Developing a vaccine to prevent RSV, a cause of serious respiratory infections in infants (children)


What is the purpose of this study?

We are researching a new vaccine against respiratory syncytial virus (RSV), a highly infectious respiratory (lung) illness which is a common cause of infection in infants and can cause serious acute illness, hospitalisation and in some cases death. Despite the high disease burden, no licensed vaccine is currently available for RSV. This study is researching a new vaccine called Ad26.RSV.preF.  The main purpose of this study is to check that the vaccine is safe. We will also measure how your child’s immune system responds to the study vaccine. Across the study twelve healthy adults and 36 healthy children aged 12 to 24 months will take part. They will receive either the new vaccine Ad26.RSV.preF or placebo (a salt water injection). Participants will receive the study vaccine on 2 occasions, with 9 routine visits from a nurse or doctor, four blood tests and phone calls every 14 to 30 days over 1 year. We hope this study contributes to finding an effective vaccine against RSV.


For further information, please see the Participant Information Sheet: RSV JnJ PIS.pdf